Orexo (ORX) 주식 개요
전문 제약 회사인 Orexo AB(publ)는 미국, 유럽연합, 영국 및 전 세계에서 의약품과 디지털 치료법을 개발하고 상용화합니다. 자세히 보기
ORX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Orexo AB (publ) 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | SEK 19.82 |
| 52주 최고가 | SEK 43.40 |
| 52주 최저가 | SEK 14.38 |
| 베타 | 0.87 |
| 1개월 변동 | -1.88% |
| 3개월 변동 | -24.50% |
| 1년 변동 | 26.89% |
| 3년 변동 | 95.85% |
| 5년 변동 | -49.82% |
| IPO 이후 변동 | -77.98% |
최근 뉴스 및 업데이트
내러티브 업데이트 • Apr 25
ORX: Higher Profit Margins And Lower P/E Assumptions Will Support Future Upside
Analysts have adjusted their view on Orexo with a modest shift in price expectations in SEK terms, citing slightly higher projected profit margins at 19.52% and a lower assumed future P/E of 124.01x as key factors behind the new price target. Valuation Changes Fair Value: SEK 38.0 remains unchanged compared with the previous SEK 38.내러티브 업데이트 • Apr 09
ORX: Steady Margins And Elevated P/E Multiple Will Support Future Upside Potential
Analysts have kept their SEK price target for Orexo broadly steady, with only a marginal adjustment that reflects slightly revised views on long term profit margins and the future P/E multiple, while leaving fair value, discount rate, and revenue growth assumptions effectively unchanged. Valuation Changes Fair Value: SEK 38.0 per share, effectively unchanged from the previous SEK 38.Recent updates
내러티브 업데이트 • Apr 25
ORX: Higher Profit Margins And Lower P/E Assumptions Will Support Future Upside
Analysts have adjusted their view on Orexo with a modest shift in price expectations in SEK terms, citing slightly higher projected profit margins at 19.52% and a lower assumed future P/E of 124.01x as key factors behind the new price target. Valuation Changes Fair Value: SEK 38.0 remains unchanged compared with the previous SEK 38.내러티브 업데이트 • Apr 09
ORX: Steady Margins And Elevated P/E Multiple Will Support Future Upside Potential
Analysts have kept their SEK price target for Orexo broadly steady, with only a marginal adjustment that reflects slightly revised views on long term profit margins and the future P/E multiple, while leaving fair value, discount rate, and revenue growth assumptions effectively unchanged. Valuation Changes Fair Value: SEK 38.0 per share, effectively unchanged from the previous SEK 38.내러티브 업데이트 • Mar 26
ORX: Stable Margins And High P/E Multiple Will Support Upside Potential
Analysts have kept their SEK fair value estimate for Orexo broadly unchanged at SEK38.0, reflecting only minor tweaks to long term margin and P/E assumptions rather than any shift in the core thesis. Valuation Changes Fair Value: SEK38.0 remains essentially unchanged compared with the prior SEK38 estimate.내러티브 업데이트 • Mar 12
ORX: Future P/E Support Will Rely On Stable Margins
Analysts have kept their SEK fair value estimate for Orexo broadly unchanged at SEK 38.0. This reflects only minor tweaks to underlying assumptions, such as slightly higher modeled revenue growth and a marginally lower future P/E multiple. Valuation Changes Fair Value: SEK 38.0 per share, unchanged from the prior SEK 38 estimate.내러티브 업데이트 • Feb 25
ORX: Future P E Multiple Will Rely On Sustained Margin Support
Analysts have raised their price target for Orexo to SEK 38, citing an assumed revenue growth rate of 35% and a projected future P/E of about 129, while forecast profit margins are expected to ease to around 19%. Valuation Changes Fair Value: SEK 38 is unchanged, with the updated estimate remaining at SEK 38.0. Discount Rate: 5.224% is unchanged between the previous and updated assumptions.내러티브 업데이트 • Feb 06
ORX: Higher Required Return Will Still Support Very Large Future P E Multiple
Narrative Update Analysts have trimmed their price target on Orexo to US$38.00, reflecting slightly higher discount rate assumptions and a modestly lower profit margin outlook. They are still applying a very large forward P/E multiple that keeps the fair value estimate unchanged at US$38.00.내러티브 업데이트 • Jan 22
ORX: Stable Assumptions And Elevated P/E Will Support Long Term Upside
Analysts have kept their fair value target for Orexo unchanged at $38.00, citing largely stable assumptions around the discount rate, revenue expectations, profit margin, and a very high forward P/E estimate. Valuation Changes Fair Value: Kept unchanged at SEK 38.00 per share, reflecting stable core assumptions.내러티브 업데이트 • Jan 07
ORX: Revised Earnings Assumptions Will Shape Balanced Long Term Prospects
Analysts have raised their price target on Orexo from SEK 31 to SEK 38, citing a substantial revision to future P/E assumptions and significantly lower revenue growth expectations, while keeping profit margin and discount rate inputs broadly unchanged. Valuation Changes Fair Value Target: raised from SEK 31 to SEK 38, reflecting a higher indicated equity value per share.내러티브 업데이트 • Dec 14
ORX: New Science Park Facilities Will Support Stronger Long Term Prospects
Analysts have modestly raised their price target on Orexo to $31.00, highlighting a slightly richer future earnings multiple that is expected to offset a small anticipated erosion in long term profit margins. What's in the News Relocating to new, modern premises in Uppsala Science Park to support the next phase of the company’s development and growth (Key Developments) New facilities include laboratories, cleanrooms, and flexible office spaces designed to strengthen research and development capabilities (Key Developments) Site designed with a clear sustainability profile, featuring energy and cost efficient solutions to reduce environmental impact (Key Developments) Move aims to foster greater collaboration and innovation with partners, academia, healthcare providers, and patients (Key Developments) Valuation Changes Fair Value: Unchanged at SEK 31.0 per share, indicating no revision to the central valuation estimate.내러티브 업데이트 • Nov 28
ORX: New Facility Move And R&D Will Drive Future Performance
Analysts have updated their price target for Orexo to $31.00. They are maintaining their previous estimate, as underlying assumptions around revenue growth and discount rates remain largely unchanged.내러티브 업데이트 • Nov 13
ORX: Future Profit Margin Gains And R&D Move To Support Outlook
Narrative Update on Orexo Analysts have maintained their fair value estimate for Orexo at $31.00, citing stable expectations for revenue growth and recent improvements in profit margin projections as key factors supporting their unchanged price target. What's in the News Orexo AB is relocating to modern premises in Uppsala Science Park to strengthen research and development, enhance collaboration, and promote sustainability within its operations (Key Developments).분석 기사 • Nov 02
Why Investors Shouldn't Be Surprised By Orexo AB (publ)'s (STO:ORX) 28% Share Price Plunge
Orexo AB (publ) ( STO:ORX ) shares have retraced a considerable 28% in the last month, reversing a fair amount of their...내러티브 업데이트 • Oct 30
ORX: Relocation And In-Vivo Results Will Support Measured Opportunity Ahead
Analysts have raised their price target for Orexo to $31.00 per share. This update reflects improving revenue growth forecasts and a slightly higher projected profit margin.내러티브 업데이트 • Oct 16
Zubsolv Litigation Settlement And OX640 Progress Will Secure Stability
Analysts have raised their price target for Orexo from $21.50 to $31.00. This decision is based on updated valuation methodologies, even as growth and margin expectations have been slightly adjusted.분석 기사 • Sep 16
There's No Escaping Orexo AB (publ)'s (STO:ORX) Muted Revenues Despite A 29% Share Price Rise
Orexo AB (publ) ( STO:ORX ) shareholders have had their patience rewarded with a 29% share price jump in the last...분석 기사 • Jun 10
Orexo AB (publ) (STO:ORX) Shares Fly 32% But Investors Aren't Buying For Growth
Orexo AB (publ) ( STO:ORX ) shareholders have had their patience rewarded with a 32% share price jump in the last...분석 기사 • May 09
Orexo AB (publ) (STO:ORX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
Orexo AB (publ) ( STO:ORX ) investors will be delighted, with the company turning in some strong numbers with its...분석 기사 • May 02
Shareholders May Not Be So Generous With Orexo AB (publ)'s (STO:ORX) CEO Compensation And Here's Why
Key Insights Orexo to hold its Annual General Meeting on 8th of May CEO Nikolaj Sorensen's total compensation includes...
새로운 내러티브 • Apr 10
Zubsolv Litigation Settlement And OX640 Progress Will Secure Stability
Legal settlements and strategic changes stabilize revenue streams, enhancing future planning and financial clarity for Orexo.분석 기사 • Dec 20
A Piece Of The Puzzle Missing From Orexo AB (publ)'s (STO:ORX) 105% Share Price Climb
Orexo AB (publ) ( STO:ORX ) shareholders would be excited to see that the share price has had a great month, posting a...분석 기사 • Nov 05
Orexo AB (publ) (STO:ORX) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
The Orexo AB (publ) ( STO:ORX ) share price has fared very poorly over the last month, falling by a substantial 26...분석 기사 • Aug 02
Orexo AB (publ) (STO:ORX) Might Not Be As Mispriced As It Looks After Plunging 28%
Orexo AB (publ) ( STO:ORX ) shareholders won't be pleased to see that the share price has had a very rough month...분석 기사 • Jul 20
Orexo AB (publ) (STO:ORX) Just Reported Earnings, And Analysts Cut Their Target Price
The analyst might have been a bit too bullish on Orexo AB (publ) ( STO:ORX ), given that the company fell short of...분석 기사 • May 29
Orexo AB (publ) (STO:ORX) Soars 28% But It's A Story Of Risk Vs Reward
Despite an already strong run, Orexo AB (publ) ( STO:ORX ) shares have been powering on, with a gain of 28% in the last...분석 기사 • Apr 03
Orexo AB (publ)'s (STO:ORX) Business And Shares Still Trailing The Industry
Orexo AB (publ)'s ( STO:ORX ) price-to-sales (or "P/S") ratio of 0.9x might make it look like a strong buy right now...분석 기사 • Dec 09
We Think Orexo (STO:ORX) Has A Fair Chunk Of Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...주주 수익률
| ORX | SE Pharmaceuticals | SE 시장 | |
|---|---|---|---|
| 7D | 7.6% | 3.1% | 2.7% |
| 1Y | 26.9% | -9.4% | 12.8% |
수익률 대 산업: ORX은 지난 1년 동안 -9.4%의 수익을 기록한 Swedish Pharmaceuticals 산업보다 더 좋은 성과를 냈습니다.
수익률 대 시장: ORX은 지난 1년 동안 12.8%를 기록한 Swedish 시장보다 더 좋은 성과를 냈습니다.
주가 변동성
| ORX volatility | |
|---|---|
| ORX Average Weekly Movement | 6.1% |
| Pharmaceuticals Industry Average Movement | 7.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in SE Market | 13.5% |
| 10% least volatile stocks in SE Market | 3.7% |
안정적인 주가: ORX는 지난 3개월 동안 Swedish 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: ORX의 주간 변동성(6%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1994 | 65 | Nikolaj Sorensen | www.orexo.com |
전문 제약 회사인 오렉소 AB(publ)는 미국, 유럽연합, 영국 및 전 세계에서 의약품과 디지털 치료법을 개발 및 상용화하는 기업입니다. 주요 제품으로는 오피오이드 사용 장애 치료를 위한 주브솔브 정제, 암 환자의 획기적인 통증 치료를 위한 애브스트랄, 불면증 치료를 위한 에드루아르 등이 있습니다. 또한 오피오이드 과다 복용 치료제 OX124, 구조 약물 및 오피오이드 과다 복용 치료제 OX125, 분말 기반 에피네프린으로 아나필락시스를 치료하는 OX640, 자궁내막증 치료제 OX-MPI를 개발 중입니다.
Orexo AB (publ) 기초 지표 요약
| ORX 기초 통계 | |
|---|---|
| 시가총액 | SEK 695.64m |
| 순이익 (TTM) | -SEK 417.90m |
| 매출 (TTM) | SEK 17.80m |
38.9x
주가매출비율(P/S)-1.7x
주가수익비율(P/E)ORX는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| ORX 손익계산서 (TTM) | |
|---|---|
| 매출 | SEK 17.80m |
| 매출원가 | SEK 10.30m |
| 총이익 | SEK 7.50m |
| 기타 비용 | SEK 425.40m |
| 순이익 | -SEK 417.90m |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
Jul 16, 2026
| 주당순이익(EPS) | -11.97 |
| 총이익률 | 42.13% |
| 순이익률 | -2,347.75% |
| 부채/자본 비율 | 0% |
ORX의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/25 19:43 |
| 종가 | 2026/05/25 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Orexo AB (publ)는 8명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| null null | ABG Sundal Collier |
| Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |
| Mattias Häggblom | Danske Bank |